• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Exogenous glutathione exerts a therapeutic effect in ischemic stroke rats by interacting with intrastriatal dopamine
Acta Pharmacol Sin. 2021 May 25. doi: 10.1038/s41401-021-00650-3. Online ahead of print.ABSTRACTWe previously showed that oral administration of exogenous glutathione (GSH) exerted a direct and/or indirect therapeutic effect on ischemic stroke rats, but the underlying mechanisms remain elusive. In the current study, we conducted a quantitative proteomic analysis to explore the pathways mediating the therapeutic effect of GSH in cerebral ischemia/reperfusion (I/R) model rats. Rats were subjected to middle cerebral artery occlusion (MCAO) for 2 h followed by reperfusion. The rats were treated with GSH (250 mg/kg, ig) or levo...
Source: Acta Pharmacologica Sinica - May 26, 2021 Category: Drugs & Pharmacology Authors: He Wang Yi-Sha Du Wen-Shuo Xu Chang-Jian Li Hong Sun Kang-Rui Hu Yuan-Zhuo Hu Teng-Jie Yu Hui-Min Guo Lin Xie Guang-Ji Wang Yan Liang Source Type: research

A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury.
CONCLUSIONS: The pharmacologic agent with the most supporting literature is amantadine used for cognitive improvement after TBI. Other neurostimulants with positive, despite more limited, evidence include methylphenidate, modafinil, levodopa, and citalopram. Caution is warranted with other neurostimulants given higher rates of adverse effects or lack of benefit observed in clinical trials. PMID: 33435717 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - January 12, 2021 Category: Drugs & Pharmacology Authors: Kakehi S, Tompkins DM Tags: Ann Pharmacother Source Type: research

Safety and efficacy of co-careldopa as an add-on therapy to occupational and physical therapy in patients after stroke (DARS): a randomised, double-blind, placebo-controlled trial
Publication date: June 2019Source: The Lancet Neurology, Volume 18, Issue 6Author(s): Gary A Ford, Bipin B Bhakta, Alastair Cozens, Suzanne Hartley, Ivana Holloway, David Meads, John Pearn, Sharon Ruddock, Catherine M Sackley, Eirini-Christina Saloniki, Gillian Santorelli, Marion F Walker, Amanda J FarrinSummaryBackgroundDopamine is a key modulator of striatal function and learning and might improve motor recovery after stroke. Previous small trials of dopamine agonists after stroke provide equivocal evidence of effectiveness on improving motor recovery. We aimed to assess the safety and efficacy of co-careldopa plus routi...
Source: The Lancet Neurology - May 22, 2019 Category: Neurology Source Type: research

Early reperfusion therapy in acute ischemic stroke after recent myocardial infarction
ABSTRACT Most known by his literary ability, the words of the neurologist Oliver Sacks (1933-2015) also had an impact on scientific community about the role of levodopa on parkinsonisms. Different from the most authors and based on his experience described on the book “ Awakenings ” , he had a pessimistic opinion about levodopa, which was related on many articles written by himself and colleagues in early 1970s. We reviewed the scientific contribution of Oliver Sacks associated to levodopa therapy on parkinsonisms, and how he advised caution with its complications before the majority of physicians.RESUMO Mais conhecido...
Source: Arquivos de Neuro-Psiquiatria - August 22, 2016 Category: Neurology Source Type: research

The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
CONCLUSIONS: Oral administration of Levodopa in the treatment of PD can cause HHcy, which can result in increased occurrence of ischemic stroke. Supplementation of methylcobalamin and folic acid can effectively reduce Hcy level and thereby prevent the occurrence of ischemic stroke. PMID: 27338068 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - June 25, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Holmes’ tremor as a delayed complication of thalamic stroke
We present a 75-year-old man who developed a disabling tremor 1year after a posterolateral thalamic stroke. This tremor had low frequency (3–4Hz), did not disappear on focus and was exacerbated by maintaining a static posture and on target pursuit, which made it very difficult to perform basic functions. MRI demonstrated an old ischemic lesion at the left posterolateral thalamus. Treatment with levodopa led to symptom control. Lesions in the midbrain, cerebellum and thalamus may cause Holmes’ tremor. Delayed onset of symptoms is usually seen, sometimes appearing 2years after the original injury. This may be due to matu...
Source: Journal of Clinical Neuroscience - November 21, 2015 Category: Neuroscience Source Type: research

Dynamics of major histocompatibility complex class II-positive cells in the postischemic brain - influence of levodopa treatment
Conclusions: Results suggest that dopamine signaling is involved in the adaptive immune response after stroke and involves microglia/macrophages.
Source: Journal of Neuroinflammation - August 23, 2014 Category: Neurology Authors: Enida KuricKarsten Ruscher Source Type: research

Reduction of rat brain CD8+ T‐cells by levodopa/benserazide treatment after experimental stroke
This study was conducted to investigate if treatment with levodopa, potentially acting as an immunomodulator, affects the T‐cell accumulation in the post‐ischemic brain. Male Sprague–Dawley rats were subjected to transient occlusion of the middle cerebral artery (tMCAO) for 105 min followed by levodopa/benserazide treatment (20 mg/kg/15 mg/kg) for 5 days initiated on day 2 post‐stroke. One week after tMCAO, T‐cell populations were analysed from brains, and levels of interleukin (IL)‐1β, chemokine (C‐X‐C motif) ligand 1, IL‐4, IL‐5, interferon gamma and IL‐13 were analysed. After levodopa/benseraz...
Source: European Journal of Neuroscience - April 1, 2014 Category: Neuroscience Authors: Enida Kuric, Karsten Ruscher Tags: Research Report Source Type: research

Dopamine receptor activation increases glial cell line-derived neurotrophic factor in experimental stroke.
Abstract Treatment with levodopa enhances functional recovery after experimental stroke but its mechanisms of action are elusive. Reactive astrocytes in the ischemic hemisphere are involved in mechanisms promoting recovery and also express dopamine 1 (D1) and dopamine 2 (D2) receptors. Here we investigated if the activation of astrocytic dopamine receptors (D1 and D2) regulates the expression of glial cell line-derived neurotrophic factor (GDNF) after combined in vitro hypoxia/aglycemia (H/A) and studied the expression of GDNF in the ischemic brain after treatment with levodopa/benserazide following transient occl...
Source: Experimental Neurology - May 9, 2013 Category: Neurology Authors: Kuric E, Wieloch T, Ruscher K Tags: Exp Neurol Source Type: research

Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone
ABSTRACT The controlled trial Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) reported an unexpected increase in acute myocardial infarction (AMI) with entacapone use in patients with Parkinson's disease (PD). The authors investigated whether entacapone increased cardiovascular and mortality risk compared with the use of a non‐levodopa dopamine agonist (DA) or a selective monoamine oxidase type‐B inhibitor (MAOBI). Using national Medicare data, a new‐user cohort of elderly patients with PD treated with entacapone was propensity score (PS) matched with new users of either DA or MAOBI. T...
Source: Movement Disorders - February 26, 2013 Category: Neurology Authors: David J. Graham, James R. Williams, Ya‐Hui Hsueh, Katlyn Calia, Mark Levenson, Simone P. Pinheiro, Thomas E. MaCurdy, David Shih, Chris Worrall, Jeffrey A. Kelman Tags: Research Article Source Type: research